8-K: MIRA Pharma Advances Ketamir-2, Preclinical Pipeline

MIRA Pharmaceuticals announced the initiation of final dosing for its Phase 1 Ketamir-2 trial and outlined plans for Phase 2a, partnering, and preclinical pipeline advancement.

Summary

• Initiated dosing in the final cohort of the Phase 1 multiple ascending dose (MAD) clinical trial for Ketamir-2, with 50 healthy volunteers already dosed and 6 subjects remaining.
• Expects to complete the Phase 1 clinical program for Ketamir-2 by the end of the first quarter of 2026.
• Finalizing the Phase 2a proof-of-concept study in chemotherapy-induced peripheral neuropathy (CIPN) and plans to submit the protocol to the FDA after Phase 1 completion.
• Anticipates initiating the Phase 2a study in the second quarter of 2026, pending regulatory feedback.
• Intends to pursue FDA Fast Track designation for Ketamir-2 for CIPN due to the lack of approved therapies.
• Plans to engage in partnering discussions at the BIO Partnering Investment & Growth Summit in March 2026.
• Will present Phase 1 data on Ketamir-2 at the American Association for Cancer Research (AACR) Annual Meeting in April 2026.
• Provided updates on preclinical programs: SKNY-1 (weight loss, nicotine addiction) and MIRA-55 (inflammatory pain), both targeting IND-enabling status by year-end 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, reflecting steady progress in MIRA Pharmaceuticals' clinical and preclinical pipeline, particularly with Ketamir-2 advancing towards Phase 2a and the strategic pursuit of FDA Fast Track designation.

Positives

• Advancement of Ketamir-2 into the final cohort of its Phase 1 trial, indicating progress towards clinical development.
• Anticipated completion of the Phase 1 program by Q1 2026, providing a clear timeline for the next stage.
• Plans to initiate a Phase 2a study for Ketamir-2 in CIPN, addressing an unmet medical need with no FDA-approved therapies.
• Intention to pursue FDA Fast Track designation for Ketamir-2, which could expedite regulatory review.
• Engagement in partnering discussions and presentation of Phase 1 data at major industry conferences (BIO Summit, AACR Annual Meeting) indicates proactive business development and scientific dissemination.
• Progress in preclinical pipeline programs SKNY-1 and MIRA-55, with a target of IND-enabling status by year-end 2026, diversifying future growth potential.

Risks

• Initiation of the Phase 2a study is "subject to regulatory feedback," indicating potential for delays or modifications based on FDA input.
• The success of preclinical programs SKNY-1 and MIRA-55 in achieving IND-enabling status by year-end 2026 is an objective, not a guarantee, and depends on ongoing CMC optimization.

Future Outlook

MIRA Pharmaceuticals expects to complete its Phase 1 clinical program for Ketamir-2 by the end of the first quarter of 2026 and anticipates initiating the Phase 2a study in the second quarter of 2026, pending regulatory feedback. The company also aims to advance its preclinical programs, SKNY-1 and MIRA-55, to IND-enabling status by year-end 2026, and plans to pursue FDA Fast Track designation for Ketamir-2.

Management Comments

• "The Company expects to complete the Phase 1 clinical program by the end of the first quarter of 2026."
• "The Company is currently finalizing its Phase 2a proof-of-concept study in chemotherapy-induced peripheral neuropathy (CIPN), including clinical site selection, and plans to submit the Phase 2a protocol to the U.S. Food and Drug Administration following completion of Phase 1."
• "Subject to regulatory feedback, the Company anticipates initiating the Phase 2a study in the second quarter of 2026."
• "Given the oncology-related nature of CIPN and the lack of FDA-approved therapies, the Company intends to pursue FDA Fast Track designation for Ketamir-2 as the program advances."
• "Both programs [SKNY-1 and MIRA-55] are currently undergoing CMC optimization, with the objective of advancing each into IND-enabling status by year-end 2026."

Industry Context

StockSavvy.ai notes that the advancement of Ketamir-2 into Phase 2a for chemotherapy-induced peripheral neuropathy (CIPN) positions MIRA Pharmaceuticals in a therapeutic area with significant unmet need, as there are currently no FDA-approved therapies for CIPN. The pursuit of FDA Fast Track designation is a common strategy for companies targeting serious conditions with limited treatment options, potentially accelerating market entry. The development of SKNY-1 for weight loss and nicotine addiction, and MIRA-55 for inflammatory pain, aligns with broader industry trends focusing on novel small molecules for metabolic and pain disorders, while attempting to mitigate side effects seen with existing therapies like GLP-1s.

Stakeholder Impact

• Shareholders: Potential for increased value due to clinical pipeline advancement and strategic business development activities.
• Patients (CIPN): Hope for a new therapeutic option if Ketamir-2 proves safe and effective, especially given the lack of FDA-approved treatments.
• FDA: Will review Phase 2a protocol and Fast Track designation request, influencing the drug's development timeline.
• Potential Partners: Opportunity for collaboration on Ketamir-2 or other pipeline assets.

Next Steps

• Complete dosing in the final cohort of the Phase 1 clinical trial for Ketamir-2.
• Complete the Phase 1 clinical program for Ketamir-2 by the end of Q1 2026.
• Submit the Phase 2a protocol for Ketamir-2 to the U.S. Food and Drug Administration.
• Initiate the Phase 2a study for Ketamir-2 in Q2 2026, subject to regulatory feedback.
• Engage in partnering discussions at the BIO Partnering Investment & Growth Summit in March 2026.
• Present Phase 1 data on Ketamir-2 at the American Association for Cancer Research (AACR) Annual Meeting in April 2026.
• Continue CMC optimization for SKNY-1 and MIRA-55 with the objective of advancing them into IND-enabling status by year-end 2026.
• Pursue FDA Fast Track designation for Ketamir-2.

Key Dates

Recommendation

The filing indicates steady progress in MIRA Pharmaceuticals' clinical development of Ketamir-2 and its preclinical pipeline. While the advancement to Phase 2a and pursuit of Fast Track designation are positive signals, the company remains in early-stage development with no immediate revenue-generating products. The success of clinical trials is inherently uncertain, and the stock's valuation will largely depend on future data readouts. Therefore, a 'hold' recommendation is appropriate for investors to monitor upcoming milestones and regulatory feedback before making further investment decisions.

Keywords

MIRA Pharmaceuticals, Ketamir-2, Phase 1 Clinical Trial, Phase 2a Study, Chemotherapy-Induced Peripheral Neuropathy, CIPN, FDA Fast Track, NMDA Receptor Antagonist, SKNY-1, MIRA-55, Weight Loss, Nicotine Addiction, Inflammatory Pain, Preclinical Pipeline, Biotechnology, Pharmaceuticals, Clinical Development